Company / R&D Expense
Eloxx Pharmaceuticals, Inc. R&D Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$8.6M
FY2025
5-year range
$2.1M / $8.6M
FY2021-FY2025
Trend
+157.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $2M to $9M over the past 10 years.
Based on SEC 10-K filings.
$9M in FY2025 with a 10-year CAGR of +15.2%.
Improved from $2M to $9M over the past 10 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +15.2%
Key checks
Key Insights
- In FY2025, r&d expense increased 157.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.6M | +157.5% |
| FY2016 | $3.3M | +60.0% |
| FY2015 | $2.1M | -18.7% |
| FY2014 | $2.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026